Prodoc AI, a Bengaluru-based healthcare software company, has raised an undisclosed seed round led by the family office of Dr Arokiaswamy Velumani, the founder of diagnostics chain Thyrocare. The round, announced on 30 September 2026, also included two existing customers of the platform, Dr Kunal Shet and Parth D. Bhasin, who invested alongside the family office.
The participation of customers as investors is unusual and telling. It suggests that hospital operators who use the product see enough value in it to put their own money behind the company.
The same family office led a ₹1,750 crore Series C round in electric scooter maker Simple Energy on the same day, underscoring its growing role as a source of capital for Indian companies across sectors.
A capital-efficient path to 100 hospitals
Prodoc AI was founded in 2022 by Asit Kumar Vidyarthi, who serves as chief executive, and Raghuvamshi Thakur, the chief operating officer. The company was incorporated as Growth Hacker Consulting Private Limited in January 2022.
Before this seed round, it had raised only about ₹1.7 crore in two angel rounds, in September 2022 and November 2023, from around 20 individual investors. On that modest capital base, the company has deployed its platform in more than 100 hospitals and now handles more than one million patient interactions each month.
Its financial scale remains small. For the year to March 2025, Prodoc AI reported revenue of ₹74 lakh, up 56% from the previous year, and a net loss of ₹1.21 crore. But its reach across hospitals suggests a product with strong adoption relative to the capital invested.
What the platform does
Prodoc AI's core product is what it calls a Patient Journey OS. Rather than asking hospitals to replace their existing software, it sits on top of the systems they already use and connects them. It brings patient data from medical records, billing and telephone systems into one place, creating what the company describes as an intelligence layer that brings patient context together and coordinates workflows.
The platform's modules cover patient acquisition and appointment conversion, outpatient department (OPD) intelligence, inpatient (IPD) care coordination, follow-ups and patient retention, and partner and referral management. It also includes voice AI capabilities and a studio for building AI agents.
On the technical side, Prodoc AI has more than 50 software integrations, holds ISO 27001 certification, says it is HIPAA compliant and supports the HL7 FHIR standard for exchanging healthcare data. It has also built for compliance with India's data protection rules.
Its customers include MGM Healthcare, Ujala Cygnus, RJN Apollo Spectra, Madhavbaug and Unicare.
Why integration matters in Indian hospitals
Indian hospitals, particularly mid-sized private hospitals and regional chains, often run a patchwork of software systems. A hospital may use one system for electronic medical records, another for billing, a third for lab results and a separate call centre platform for appointments. These systems rarely communicate well, which leads to missed follow-ups, lost referrals, billing errors and a poor patient experience.
Replacing all of them with a single integrated system is expensive and disruptive. Prodoc AI's approach of connecting existing systems offers a less risky path to digital coordination, which is particularly attractive to hospitals with limited IT budgets.
The government's push for digital health infrastructure, including the Ayushman Bharat Digital Mission and its health ID and data exchange framework, has also encouraged hospitals to modernise how they manage patient information.
The agentic AI ambition
The new funding will be used to develop agentic AI capabilities: software agents that can carry out tasks with limited human supervision. Prodoc AI plans to build agents for care coordination, patient engagement, operations and revenue management, and to expand its integrations.
In practice, such agents could automatically remind patients about follow-up appointments, coordinate discharge processes, chase pending insurance documentation, answer routine patient queries by voice or message, and flag patients at risk of missing treatment.
Hospitals globally are experimenting with AI agents to reduce administrative workload, which consumes a large share of staff time. In India, where hospitals often face shortages of trained nursing and administrative staff, automation of routine coordination tasks could free up time for patient care.
There are, however, legitimate concerns about deploying autonomous software in clinical settings. Errors in patient communication can have serious consequences, and hospitals must ensure that AI agents handle sensitive health data in line with India's Digital Personal Data Protection Act. That is why most hospital deployments of AI start with administrative and coordination tasks rather than clinical decisions, keeping doctors and nurses firmly in control of treatment. Prodoc AI's focus on care coordination, engagement, operations and revenue cycle management fits that cautious, step-by-step approach.
Experienced advisers
Prodoc AI has assembled an advisory board with senior healthcare experience, including Raj Gore, former chief executive of cancer care chain HCG, and Dr Nandakumar Jairam, formerly of Columbia Asia Group. Their involvement gives the company credibility with hospital leaders, who are often cautious about adopting new technology.
The investor angle
Dr Velumani built Thyrocare into one of India's best-known diagnostics companies by focusing on high volumes and low costs, before selling a controlling stake to PharmEasy's parent in 2021. His family office's investment in Prodoc AI brings deep understanding of healthcare operations to the startup.
For a seed-stage company, that combination of capital and operating experience can be as valuable as the money itself, particularly when selling into conservative hospital customers. Hospital technology purchases in India are often decided by promoters and senior doctors rather than IT departments, and an investor with credibility in the medical community can help open those doors.
What comes next
Prodoc AI now faces the challenge of turning wide adoption into meaningful revenue. Its current revenue is small relative to the number of hospitals using the platform, which suggests either low pricing or early-stage contracts. Agentic AI products, which can directly reduce costs or increase revenue for hospitals, may allow the company to charge more for measurable outcomes.
If it succeeds, Prodoc AI could become an important layer in the digital infrastructure of India's private hospitals, and a model for how AI can improve patient care in health systems that cannot afford to rebuild their technology from scratch.
